# A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)

> **NCT00535028** · PHASE2 · COMPLETED · sponsor: **Aerovance, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** AER 001
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00535028
- **Lead sponsor:** Aerovance, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2007-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535028, "A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00535028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*